PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

Barbara Muz; Maurizio Buggio; Feda Azab; Pilar De La Puente; Mark Fiala; Mahesh V. Padval; David T. Weaver; Jonathan A. Pachter; Ravi Vij; Abdel Kareem Azab

doi:10.3324/haematol.2018.194688

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

Barbara Muz
, Maurizio Buggio
, Feda Azab
, Pilar De La Puente
, Mark Fiala
, Mahesh V. Padval
, David T. Weaver
, Jonathan A. Pachter
, Ravi Vij
, Abdel Kareem Azab

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e310-e313
Journal	Haematologica
Volume	104
Issue number	7
DOIs	https://doi.org/10.3324/haematol.2018.194688
State	Published - Jun 30 2019

Access to Document

10.3324/haematol.2018.194688

Cite this

@article{24e80307060c42d593dfda35c4ad6e2c,

title = "PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma",

author = "Barbara Muz and Maurizio Buggio and Feda Azab and \{De La Puente\}, Pilar and Mark Fiala and Padval, \{Mahesh V.\} and Weaver, \{David T.\} and Pachter, \{Jonathan A.\} and Ravi Vij and Azab, \{Abdel Kareem\}",

note = "Funding Information: 1Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA; 2Nanomedicine Laboratory, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester ,UK; 3Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA and 4Verastem Inc., Needham, MA, USA Funding: this study was supported partially by a research grant from Verastem, Inc. and by an award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH under (U54CA199092). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.",

year = "2019",

month = jun,

day = "30",

doi = "10.3324/haematol.2018.194688",

language = "English",

volume = "104",

pages = "e310--e313",

journal = "Haematologica",

issn = "0390-6078",

number = "7",

}

TY - JOUR

T1 - PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

AU - Muz, Barbara

AU - Buggio, Maurizio

AU - Azab, Feda

AU - De La Puente, Pilar

AU - Fiala, Mark

AU - Padval, Mahesh V.

AU - Weaver, David T.

AU - Pachter, Jonathan A.

AU - Vij, Ravi

AU - Azab, Abdel Kareem

N1 - Funding Information: 1Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA; 2Nanomedicine Laboratory, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester ,UK; 3Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA and 4Verastem Inc., Needham, MA, USA Funding: this study was supported partially by a research grant from Verastem, Inc. and by an award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH under (U54CA199092). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

PY - 2019/6/30

Y1 - 2019/6/30

UR - https://www.scopus.com/pages/publications/85069207718

U2 - 10.3324/haematol.2018.194688

DO - 10.3324/haematol.2018.194688

M3 - Article

C2 - 30655367

AN - SCOPUS:85069207718

SN - 0390-6078

VL - 104

SP - e310-e313

JO - Haematologica

JF - Haematologica

IS - 7

ER -

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

Access to Document

Other files and links

Cite this